- Coronado Biosciences (CNDO) initiates a Phase 2 study of CNDO-201 in patients with ulcerative colitis.
- The trial is sponsored by the National Institutes of Health and will "evaluate the [drug's] effect on clinical response of UC, intestinal mucosal immunological response, and inflammatory markers."
- Primary endpoint is clinical response.
- This is the third Phase 2 trial for CNDO-201. (PR)